Neuro Startup Makes Debut With $20.9M From Novo, Johnson & Johnson Post author:Sam Post published:February 8, 2018 Post category:BioPharma Syndesi will work to modulate the synaptic vesicle protein SV2A. Source: BioSpace You Might Also Like Arcturus CEO Ousted, Effective Immediately February 1, 2018 Akers Biosciences Reports Preliminary Unaudited Earnings Highlights For Fiscal Year 2016 March 30, 2017 UK Science Gets More Post-Brexit Love From GlaxoSmithKline, Other Drugmakers December 5, 2017
Akers Biosciences Reports Preliminary Unaudited Earnings Highlights For Fiscal Year 2016 March 30, 2017
